Notch1 in Cancer Therapy: Possible Clinical Implications and Challenges
- 1 November 2020
- journal article
- review article
- Published by Elsevier in Molecular Pharmacology
- Vol. 98 (5) , 559-576
Abstract
The Notch family consists of four highly conserved transmembrane receptors, the release of the active intracellular domain requires the enzymatic activity of gamma secretase. Notch is involved in embryonic development and in many physiological processes of normal cells where it regulates growth, apoptosis and differentiation. Notch 1, a member of the Notch family, is implicated in many types of cancer, including breast cancer (especially triple negative breast cancer), leukemias, brain tumors, and many others. Notch 1 is tightly connected to many signaling pathways that are therapeutically involved in tumorigenesis. Together, they impact apoptosis, proliferation, chemosensitivity, immune-response and the population of cancer stem cells. Notch 1 inhibition can be achieved through various and diverse methods, among the most common are the gamma secretase inhibitors which produce a pan-Notch inhibition, or the use of Notch 1 siRNA or Notch 1 monoclonal antibodies (mAb) which produce a more specific blockade. Downregulation of Notch 1 can be used alone or in combination with chemotherapy where a synergistic effect and a decrease in chemoresistance can be achieved. Targeting Notch1 in cancers that harbor high expression levels of Notch 1 offers an addition to therapeutic strategies recruited for managing cancer. Considering available evidence, Notch 1 offers a legitimate target that might be incorporated in future strategies for combating cancer. In this review, the possible clinical applications of Notch 1 inhibition and the obstacles that hinder its clinical application are discussed. Significance Statement Notch 1 plays an important role in different types of cancer. Numerous approaches of Notch 1 inhibition possess potential benefits in the management of various clinical aspects of cancer. The application of different Notch 1 inhibition modalities faces many challenges.Keywords
This publication has 155 references indexed in Scilit:
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsInvestigational New Drugs, 2013
- Notch activation stimulates migration of breast cancer cells and promotes tumor growthBreast Cancer Research, 2013
- Notch receptor–ligand binding and activation: Insights from molecular studiesSeminars in Cell & Developmental Biology, 2012
- γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancerBritish Journal of Cancer, 2012
- Notch1 regulates the expression of the multidrug resistance geneABCC1/MRP1in cultured cancer cellsProceedings of the National Academy of Sciences, 2011
- Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrenceBritish Journal of Cancer, 2011
- Direct inhibition of the NOTCH transcription factor complexNature, 2009
- Inhibition of γ-secretase induces G2/M arrest and triggers apoptosis in breast cancer cellsBritish Journal of Cancer, 2009
- γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemiaNature Medicine, 2008
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007